Tenax Therapeutics Faces Securities Class Action Lawsuit
A New York law firm has filed a class action against Tenax Therapeutics, targeting investors who bought TENX shares over a nearly three-year window.
Law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against Tenax Therapeutics, Inc., traded on the Nasdaq under the ticker TENX, according to a notice released October 30, 2026. The suit seeks to recover damages on behalf of investors who purchased TENX securities during a specified class period.
The class period identified in the complaint spans from November 13, 2023 through August 7, 2026 — a window of nearly three years. Investors who bought shares during that timeframe and sustained losses may be eligible to participate in the litigation and potentially recover damages.
Read more FP Markets: Democratic Sweep Seen as Base-Case Scenario for Markets →
The lead plaintiff deadline, the court-imposed cutoff by which an investor must apply to serve as the primary representative plaintiff in the case, is set for December 28, 2026. Securities class actions typically allow any qualifying investor to join the suit, but only those who file by the deadline can seek the lead plaintiff role, which can carry greater influence over how the case proceeds.
The lawsuit was filed in connection with alleged securities violations, though the specific claims and underlying facts driving the complaint were not fully detailed in the initial announcement. Shareholders with questions about their eligibility or potential recovery are encouraged to contact the filing firm directly before the December deadline.
Continue reading at All Financial Services & Investing
